Synairgen plc (LON:SNG – Get Rating) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 16.80 ($0.20) and traded as low as GBX 10.26 ($0.12). Synairgen shares last traded at GBX 10.48 ($0.13), with a volume of 279,653 shares.
Synairgen Stock Performance
The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.09. The stock has a market cap of £21.09 million, a price-to-earnings ratio of -74.82 and a beta of -2.20. The company has a 50 day simple moving average of GBX 13.10 and a 200 day simple moving average of GBX 16.76.
About Synairgen
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Further Reading
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在週五的交易中,Synairgen plc(倫敦股票代碼:SNG-GET Rating)的股價跌破了200日移動均線。該股的200日移動均線為16.80英鎊(合0.20美元),交易價格低至10.26英鎊(合0.12美元)。Synairgen的股票最後交易價格為10.48英鎊(0.13美元),成交量為279,653股。
Synairgen股票表現
該公司的速動比率為6.35,流動比率為6.35,債務權益比為0.09。該股市值為2109萬GB,本益比為-74.82,貝塔係數為-2.20。該公司的50日簡單移動均線切入位為13.10英鎊,200日簡單移動均線切入位為16.76英鎊。
關於Synairgen
(獲取評級)
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有:治療新冠肺炎的乙型吸入型幹擾素SG001;治療感冒和流感引起的哮喘的乙型幹擾素吸入劑;治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨床試驗;以及治療特發性肺纖維化的LXL2抑制劑。
進一步閱讀
- SVB金融崩潰對美國銀行意味著什麼
- 市場回顧周-3/6/3/10
- 2個近海鑽探公司將大賺一筆
- 未來有望實現兩位數上漲的三隻史泰博股票
- 投資者能信任消費者來提升美國戶外品牌嗎?
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。